G Protein-Coupled Receptor 40 Agonist LY2922470 Alleviates Ischemic-Stroke-Induced Acute Brain Injury and Functional Alterations in Mice

Yingyu Lu, Wan-Lu Zhou, Qinghua Cui, Chunmei CuiInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This paper investigates the potential of LY2922470, a known GPR40 agonist for type 2 diabetes, as a novel treatment for acute ischemic stroke. The study demonstrates that LY2922470 significantly reduces brain infarct size and improves motor function in mice following stroke, suggesting it could be a promising therapeutic agent.

What Problem Does This Paper Address?

Stroke is a leading cause of death and disability worldwide, with ischemic strokes accounting for the vast majority. Current treatments, like intravenous thrombolysis with tPA, are limited by a narrow therapeutic window and risk of bleeding, leaving a significant unmet need for new and effective therapies. While G protein-coupled receptor 40 (GPR40) activators have shown some neuroprotective effects, the specific potential of LY2922470, a drug already in use for type 2 diabetes, in mitigating stroke-induced brain injury remained unexplored. This paper aims to bridge this knowledge gap by evaluating LY2922470's efficacy in a mouse model of ischemic stroke.

Methods

The researchers employed a multi-pronged approach:

  • Transcriptomic Analysis & Database Screening: They first analyzed the gene expression signature induced by LY2922470 and compared it to a database of gene signatures from various small molecules (Connectivity Map). This was done to identify existing drugs with similar molecular targets or pathways that are known to be beneficial in cerebrovascular conditions.
  • In Vivo Stroke Model: A standard middle cerebral artery occlusion/reperfusion (MCAO/R) model in mice was used to simulate ischemic stroke.
  • Drug Administration: LY2922470 was administered to mice via two routes: oral administration and intraperitoneal injection, at various doses and timings, both before and after the induced stroke.
  • Neuroprotection Assessment:
    • Infarct Size Measurement: Brain tissue was stained with triphenyltetrazolium chloride (TTC) to visualize and quantify the area of dead tissue (infarct volume).
  • Functional Assessment: A grip test was used to evaluate motor function and assess the impact of the stroke and treatment on the animals' ability to perform a motor task.
  • Comparison with Existing Treatment: The efficacy of LY2922470 was compared to tPA, the current gold standard treatment for acute ischemic stroke.

Datasets

  • Connectivity Map (CMap) Database: Used to compare the transcriptomic gene signature induced by LY2922470 with those of other small molecules.
  • Mouse Transcriptomic Data: Gene fold change profiles induced by LY2922470 in A549 cells were obtained from JeaMoon Technology Co., Ltd.

Key Insights and Ideas

  • Repurposing Potential: The initial transcriptomic analysis revealed that LY2922470's gene signature closely matched those of drugs already known to have protective effects against cerebrovascular accidents and transient ischemic attacks (e.g., acetylsalicylic acid, progesterone, estradiol). This provided a strong rationale for investigating its potential in stroke.
  • Dual Administration Efficacy: LY2922470 demonstrated protective effects regardless of whether it was administered orally or via intraperitoneal injection, suggesting flexibility in its clinical application.
  • Dose-Dependent Reduction in Infarct Size: Higher doses of LY2922470 led to a more significant reduction in the volume of brain tissue damaged by the stroke.
  • Potential for Functional Recovery: While not as pronounced as infarct size reduction, LY2922470 showed a trend towards mitigating the impairment of brain function, as indicated by the grip test results.

Key Results

  • Transcriptomic Similarity: LY2922470's gene signature was found to be highly similar to those of acetylsalicylic acid, progesterone, estradiol, dipyridamole, and dihydroergotamine.
  • Oral Administration: Pre-treatment with 40 mg/kg of LY2922470 orally resulted in a substantial reduction in cerebral ischemic infarct area (20.40% ± 2.43%) compared to the untreated stroke group (45.36% ± 7.33%).
  • Intraperitoneal Injection: Administration of LY2922470 (10 mg/kg) intraperitoneally at 0h and 12h post-operation led to a marked decrease of 52.06% in cerebral ischemia size.
  • Comparison with TAK875: A similar GPR40 agonist, TAK875, at a dose of 30 mg/kg, showed nearly unnoticeable effects on cerebral ischemic injury, highlighting a potential difference in efficacy or mechanism between GPR40 agonists.
  • Comparison with tPA: The combination of LY2922470 and tPA did not show a significant disparity in cerebral infarct magnitude compared to tPA alone, suggesting LY2922470 might not offer additive benefits when used with tPA in this acute setting, or that tPA's effect is already maximal.
  • Functional Improvement Trend: The LY2922470 group showed a trend of mitigating brain function alterations in the grip test.

Limitations and Future Work

  • Mechanism of Action: The precise underlying mechanism by which LY2922470 alleviates stroke-induced brain damage remains unclear. While GPR40 activation is implicated, further investigation is needed to elucidate the specific intracellular signaling pathways involved.
  • Dosing Protocols: More research is required to establish optimal dosing protocols, including examining drug permeability across the blood-brain barrier and the impact of stroke on drug absorption.
  • "Biased Agonism": The paper speculates that the "biased agonism" of GPR40 agonists (i.e., activating only certain downstream pathways) might explain the differences in efficacy observed between LY2922470 and TAK875. This warrants further exploration.
  • Further Investigation: The authors emphasize the need for further investigation to delve into the particulars of how LY2922470 is effective in treating stroke.

Summary updated

Abstract

Stroke is a major cause of fatalities and disabilities around the world, yet the available treatments for it are still limited. The quest for more efficacious drugs and therapies is still an arduous task. LY2922470 is currently used as a G protein-coupled receptor 40 (GPR40) agonist for the treatment of type 2 diabetes. Previous studies have reported protective effects of other GPR40 activators on the brain; however, it remains unclear whether LY2922470 could be a new stroke therapy and improve the stroke-induced brain damage. Here, we first reveal that the transcriptomic gene signature induced by LY2922470 is highly similar to those induced by some agents being involved in defending from cerebrovascular accidents and transient ischemic attacks, including acetylsalicylic acid, progesterone, estradiol, dipyridamole, and dihydroergotamine. This result thus suggests that LY2922470 could have protective effects against ischemic stroke. As a result, further experiments show that giving the small molecule LY2922470 via oral administration or intraperitoneal injection was seen to have a positive effect on neuroprotection with a reduction in infarct size and an improvement in motor skills in mice. Finally, it was demonstrated that LY2922470 could successfully mitigate the harm to the brain caused by ischemic stroke.
BibTeX
@article{lu2023g,
  author = {Yingyu Lu and Wan-Lu Zhou and Qinghua Cui and Chunmei Cui},
  title = {{G Protein-Coupled Receptor 40 Agonist LY2922470 Alleviates Ischemic-Stroke-Induced Acute Brain Injury and Functional Alterations in Mice}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512244},
}
Figure